Research published in two articles in this week’s The Lancethas demonstrated that moderate-to-severe psoriasis can be effectivelytreated with the drug ustekinumab. In these PHOENIX trials, the authorshave also shown that treatment every 12 weeks maintains efficacy inmost people.As the most common immune-mediated adult skin disease, psoriasisaffects nearly 2 to 3% of the population.

This post is an original post by ScienceDaily: Skin Care News